Androgen-Dependent Rhox Homeobox Genes
雄激素依赖性 Rhox 同源盒基因
基本信息
- 批准号:7805635
- 负责人:
- 金额:$ 31.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-05-07 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:AgreementAndrogen ReceptorAndrogen Response ElementAndrogensBindingContraceptive methodsDevelopmentElementsEpididymisEventFamily memberFigs - dietaryFutureGene ClusterGene TargetingGenerationsGenesGeneticGenetic TranscriptionGerm CellsGoalsHomeobox GenesIn VitroLeadMale Contraceptive AgentsMale InfertilityMediatingMeiosisMolecularMusNamesNuclear Hormone ReceptorsOvaryParticipantPlacentaPublished CommentReproductionResearch PersonnelRoleSperm MaturationSpermatidsSpermatogenesisTestisTimeUncertaintyWorkX Chromosomebasecell typein vivointerestmalemembernovelpostnatalprogramsreceptor expressionreproductiveresponseselective expressionsertoli cellsperm celltranscription factor
项目摘要
DESCRIPTION (provided by applicant): Spermatogenesis has been known for decades to depend on androgens, but the molecular mechanism behind this has remained largely elusive. Even the cell types in the testis that drive spermatogenesis in response to androgens had not been clearly defined until recent mouse genetic studies demonstrated that at least one participant is the Sertoli cell. It is logical that the Sertoli cell would promote spermatogenesis in response to androgens, as it is in intimate contact with developing germ cells and expresses high levels of androgen receptor (AR), a nuclear hormone-receptor family member and transcription factor that must usually be bound to androgen to activate its target genes. Most androgen-regulated genes in Sertoli cells may not be direct targets of AR but instead may be regulated by androgen-regulated transcription factors. These secondary androgen-response genes have cis elements that bind to androgen-regulated transcription factors. To date, no transcription factors regulating these secondary androgen-response genes in Sertoli cells have been definitively identified. A good candidate is the founding member of the Rhox homeobox gene cluster, Rhox5 (Pem), as it is androgen regulated, selectively expressed in Sertoli cells, and necessary for normal spermatogenesis. This proposal focuses on two other androgen-regulated genes in the Rhox homeobox gene cluster, Rhox10 and Rhox11. Each is expressed at peak levels in the testes at postnatal time points that correspond to two distinct AR-dependent events during spermatogenesis: the progression of male germ cells through meiosis I and the transition of late-round spermatids into elongating spermatids. Thus, we hypothesize that Rhox10 and Rhox11 encode transcription factors that participate in mediating these two AR-dependent events. The Specific Aims of this application are (i) to identify the functions of the androgen-regulated Rhox10 and Rhox11 genes in spermatogenesis and sperm maturation in vivo; (ii) to distinguish the independent and redundant roles of the androgen-regulated Rhox5, Rhox10, and Rhox11 genes in male reproduction; and (iii) to begin to elucidate the AR-dependent gene networks that drive spermatogenesis by identifying gene targets of the androgen-regulated Rhox genes. By providing a molecular basis for androgen-driven spermatogenesis, the proposed work could ultimately lead to cures for some cases of male infertility and the development of novel male contraceptive methods.
描述(由申请人提供):几十年来,人们已经知道精子发生依赖于雄激素,但其背后的分子机制在很大程度上仍然难以捉摸。即使睾丸中响应雄激素而驱动精子发生的细胞类型也尚未明确定义,直到最近的小鼠遗传学研究证明至少一个参与者是支持细胞。顺理成章的是,支持细胞会响应雄激素而促进精子发生,因为它与发育中的生殖细胞密切接触,并表达高水平的雄激素受体(AR),雄激素受体是一种核激素受体家族成员和转录因子,通常必须与雄激素结合才能激活其靶基因。支持细胞中的大多数雄激素调节基因可能不是 AR 的直接靶标,而是可能受到雄激素调节转录因子的调节。这些次级雄激素反应基因具有与雄激素调节转录因子结合的顺式元件。迄今为止,尚未明确鉴定出调节支持细胞中这些次级雄激素反应基因的转录因子。一个很好的候选者是 Rhox 同源盒基因簇的创始成员 Rhox5 (Pem),因为它受雄激素调节,在支持细胞中选择性表达,并且是正常精子发生所必需的。该提案重点关注 Rhox 同源盒基因簇中的另外两个雄激素调节基因,Rhox10 和 Rhox11。每一种在出生后时间点在睾丸中表达达到峰值水平,对应于精子发生过程中两个不同的 AR 依赖性事件:雄性生殖细胞通过减数分裂 I 的进展以及晚轮精子细胞向伸长精子细胞的转变。因此,我们假设 Rhox10 和 Rhox11 编码参与介导这两个 AR 依赖性事件的转录因子。本申请的具体目标是(i)确定雄激素调节的Rhox10和Rhox11基因在体内精子发生和成熟中的功能; (ii) 区分雄激素调节的 Rhox5、Rhox10 和 Rhox11 基因在雄性生殖中的独立和冗余作用; (iii) 通过识别雄激素调节的 Rhox 基因的靶标,开始阐明驱动精子发生的 AR 依赖性基因网络。通过为雄激素驱动的精子发生提供分子基础,拟议的工作最终可能会治愈某些男性不育症并开发新型男性避孕方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MILES Frome WILKINSON其他文献
MILES Frome WILKINSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MILES Frome WILKINSON', 18)}}的其他基金
Cisplatin-induced epigenomic modifications in male germ cells
顺铂诱导的雄性生殖细胞表观基因组修饰
- 批准号:
9002272 - 财政年份:2015
- 资助金额:
$ 31.75万 - 项目类别:
相似海外基金
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
$ 31.75万 - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 31.75万 - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
$ 31.75万 - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
$ 31.75万 - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
$ 31.75万 - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 31.75万 - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
$ 31.75万 - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
$ 31.75万 - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
$ 31.75万 - 项目类别: